Gandeeva Therapeutics

Executive Summary

Gandeeva Therapeutics is a privately held biotech company that leverages cryo-electron microscopy (cryo-EM) and artificial intelligence to design precision medicines targeting previously undruggable protein complexes. Founded in 2020 and headquartered in Vancouver, Canada, the company has raised $150 million to build its proprietary platform. By combining high-resolution structural biology with machine learning, Gandeeva aims to accelerate the discovery and development of small-molecule and biologic therapeutics for a range of diseases, including oncology, neurology, and rare genetic disorders. The platform's ability to visualize protein interactions in atomic detail enables the rational design of molecules that modulate complex biological pathways, offering a differentiated approach compared to traditional drug discovery methods. In the near term, Gandeeva is expected to transition from platform-building to advancing its own pipeline of drug candidates toward clinical development. The company's strong financial backing and focus on high-value targets position it as a compelling player in the AI-driven drug discovery space. Key upcoming milestones include the nomination of a development candidate for its lead program, potential partnership or licensing deals with larger pharmaceutical companies seeking to leverage its cryo-EM platform, and the initiation of IND-enabling studies. Success in these areas could validate the platform and unlock significant value, though the early-stage nature of the pipeline implies inherent technological and regulatory risks.

Upcoming Catalysts (preview)

• Q4 2026Lead program development candidate nomination65% success
• H1 2027Strategic partnership or licensing deal for platform access50% success
• Q2 2027Initiation of IND-enabling studies for first candidate55% success